Editorial: Thrombophilia Diagnosis–Genetic or Functional Testing

Check with your medical library for Favaloro EJ, Moore GW, Pasalic L. Diagnosing thrombophilia: the case for genetic or functional testing? Expert Rev Mol Diagn. 2025:1-6. doi: 10.1080/14737159.2025.2588621. PMID: 41211955. Introduction The term thrombophilia defines a condition in which there is an elevated risk of thrombosis, usually venous thromboembolism (VTE), generally encompassing deep vein thrombosis […]

Comments (0)

Thrombophilia

Dec 12 2025

george

Platelet Function Preservation Following Cell Salvage

Thanks to colleague Dave McGlasson, MS, MLS for identifying this open-access original research study that describes the effects of intraoperative cell salvage on platelet function. Blum LV, Sertdere F, Iken S, et al. Preservation of platelet function after intraoperative cell salvage using the i-SEP same device in cardiac surgery. J Cardiothorac Vasc Anesth. 2025:S1053-0770(25)01058-4. doi: […]

Comments (0)

Platelet Function Testing

Dec 11 2025

george

Thrombotic Thrombocytopenic Purpura Sequelae

An ASH ’25 summary by Dr. Wolfgang Miesbach: iTTP remission ≠ cure–the vascular injury persists. TTP as a cardiovascular disease equivalent. I just finished Dr. Senthil Sukumar’s session on long-term iTTP management. This completely changed how I think about these patients, as illustrated: 28.6% of survivors → major cardiovascular events 50% → silent cerebral infarcts (vs […]

Thrombophilia

Anesthesiologists’ Approach to Perioperative Bleeding Management

ASH ’25 Report from Dr. Wolfgang Miesbach: Perioperative Bleeding Management: What 1,030+ U.S. Anesthesiologists Think About Current Challenges 50.6% practiced primarily at academic medical centers, while 42.3% worked in community hospitals, with additional representation from military/VA hospitals (3.7%). Nearly half (48.4%) worked at Level I trauma centers. The Progress… Prothrombin complex concentrates (PCCs) have become […]

Bleeding Disorders

Hemophilia Rx: “Paradox of Choice”

An ASH ’25 report from Dr. Wolfgang Miesbach: The “Paradox of Choice” is very real in Haemophilia right now. I just caught Dr. Mark Reding’s insightful presentation at ASH25, and it really highlighted that having more options doesn’t actually make the decision easier. In fact, it makes it harder. We’re looking at a massive toolkit […]

Bleeding Disorders

Associations of FVIII & FIX Levels with CVD and CVD Mortality

Go to your medical library to access this provocative journal article: Harris K, Woodward M, Folsom AR, et al. Associations between plasma levels of coagulation factors VIII and IX and incident cardiovascular disease and mortality: systematic review and meta-analysis. J Thromb Haemost. 2025:S1538-7836(25)00598-7. doi: 10.1016/j.jtha.2025.09.008. PMID: 41038279. Abstract Background: Associations of plasma levels of coagulation […]

Arterial Thrombosis

Diagnostic Equity Case: Varying INR

This question came from a patient to the Diagnostic Equity Service on 12-9-2025: I notice my INR keeps changing even though I take the same warfarin dose. Could this be a lab issue or a metabolism issue? Thank you for what you do. Abby Carroll, MS, MLS (ASCP)cm answered: In most cases, INR variability is […]

Comments (0)

Anticoagulant Therapy

Dec 8 2025

george

Asundexian Anti-XIa Antithrombotic Shows Promise

Select “Bayer’s Asundexian anti XIa antithrombin met primary efficacy and safety endpoints in a landmark phase III OCEANIC-STROKE study for secondary stroke prevention” for their press release presented at ASH 2025.

Comments (0)

Anticoagulant Therapy

Dec 8 2025

george

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 3: DOACs and Warfarin

Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory and Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, as we discuss the pathophysiology of antiphospholipid antibodies and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with APS. Click DOACs […]

Comments (1)

Anticoagulant Therapy

Dec 8 2025

george

ASH 2025 Highlight: Beyond Immunosuppression: Two New Ways to Treat ITP

David Kuter gave this presentation at ASH 2025: Immune thrombocytopenic purpura is now recognized as a disorder characterized by both reduced production and increased destruction—this understanding drives treatment selection toward achieving complete remission, rather than just disease suppression. Increase Platelet Production The latest TPO receptor agonist, hetrombopag, now in phase 3 trials, offers a direct […]

Comments (0)

Bleeding Disorders

All Posts

Editorial: Thrombophilia Diagnosis–Genetic or Functional Testing

Platelet Function Preservation Following Cell Salvage

Thrombotic Thrombocytopenic Purpura Sequelae

Anesthesiologists’ Approach to Perioperative Bleeding Management

Hemophilia Rx: “Paradox of Choice”

Associations of FVIII & FIX Levels with CVD and CVD Mortality

Diagnostic Equity Case: Varying INR

Asundexian Anti-XIa Antithrombotic Shows Promise

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 3: DOACs and Warfarin

ASH 2025 Highlight: Beyond Immunosuppression: Two New Ways to Treat ITP

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question